Stockscreener 앱 받기
1.155
8.38%
0.085
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com
Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Allarity unveils new multiple myeloma treatment predictor - Investing.com
Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com India
Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News
Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire
Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com
Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Allarity Therapeutics Restructures Board of Directors - TipRanks
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com
Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan
Allarity Therapeutics Inc. (ALLR) reports earnings - qz.com
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times
Allarity reports promising ovarian cancer trial results - Investing.com
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian
Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
Can you now get a good deal on Allarity Therapeutics Inc’s shares? - uspostnews.com
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com
Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia
SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener
1.36%
0.60%
자본화:
|
볼륨(24시간):